Evaluation of the Effect of Biofeedback on Osseous Union Using Pedobarography After Mid- and Hindfoot Arthrodesis

Sponsor
Prof. Dr. med. Arno Frigg (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04732884
Collaborator
(none)
216
2
49

Study Details

Study Description

Brief Summary

The current study aims at evaluating the effect of biofeedback of correct partial weight bearing on the rate of osseous non-union compared to conventional patient instruction without biofeedback.

Condition or Disease Intervention/Treatment Phase
  • Device: Sens2Go, Golex AG; w biofeedback
  • Device: Sens2Go, Golex AG; w/o biofeedback
N/A

Detailed Description

Post-traumatic situations or instabilities of other aetiology at the level of the foot can lead to painful degenerative arthritis that necessitates surgical arthrodesis for pain relief. Surgical arthrodesis in this region though is associated with a high risk of osseous non-union (depending on the exact location up to 40%) despite standardized preparation and fixation techniques. The development of osseous non-union is associated with certain patient characteristics like active smoking, nutrition etc. Compliance to partial weight-bearing during the early postoperative phase is another contributing factor.

The current study aims at evaluating the effect of biofeedback of correct partial weight bearing on the rate of osseous non-union compared to conventional patient instruction without biofeedback.

All patients will postoperatively be provided with a lower- leg unloading orthosis furnished with a weight sensor that will - according to randomization - give feedback if a predefined weight threshold has been crossed or just measure weight-bearing without feedback.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
216 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Monocentric, prospective, randomized, controlled trialMonocentric, prospective, randomized, controlled trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Radiologists assessing the primary outcome osseous non-union will be blind to the treatment allocation.
Primary Purpose:
Other
Official Title:
A Prospective Randomized Controlled Monocentric Trial Evaluating the Effect of Biofeedback on Osseous Union Using Pedobarography After Mid- and Hindfoot Arthrodesis
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Aug 1, 2026
Anticipated Study Completion Date :
Jan 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Weight sensor with biofeedback

Activation of the feedback function of the weight-bearing sensor as mean to possibly enhance compliance to weight-bearing instructions postoperative.

Device: Sens2Go, Golex AG; w biofeedback
The Sens2Go is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
Other Names:
  • Weight sensor with biofeedback
  • Experimental: Weight sensor without biofeedback

    Standard patient education considering postoperative weight-bearing parameters and measurement of actual weight-bearing with the sensor.

    Device: Sens2Go, Golex AG; w/o biofeedback
    Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
    Other Names:
  • Weight sensor without biofeedback
  • Outcome Measures

    Primary Outcome Measures

    1. Evaluation of the influence of weight bearing an resting time on the development of osseous non-union after surgical arthrodesis at the level of the mid- and hindfoot. [3 months]

      The primary outcome is an analysis of the rate of non-unions after mid- and hindfoot arthrodesis comparing a sensor the two patient arms with activated vs non-activated biofeedback. The rate of osseous non-unions defined as CT-morphologic union <30% of the joint surface at 3 months in relation to the provision of biofeedback.

    Secondary Outcome Measures

    1. Compliance i.e. adherence to weight bearing recommendations (≤ 15kg charge) with and without biofeedback. [6 weeks]

      All patients will be asked to wear the orthosis with integrated sensor all day long including resting times. They are furthermore instructed to follow partial weight-bearing with 15kg (for 6 weeks). The device will record load and quantity of steps over time. In the first group, a biofeedback in form of an audio-signal will warn the patient if treatment recommendations like partial weight bearing are not followed. The control intervention will be pure instruction followed by measurements. Control patients will not receive biofeedback upon transgression of recommendations.

    2. Compliance i.e. adherence to resting time recommendations (≥ 80% of time) with and without biofeedback. [6 weeks]

      All patients will be asked to wear the orthosis with integrated sensor all day long including resting times. They are furthermore instructed to reduce their activity with 80% resting time. The device will record load and quantity of steps over time. In the first group, a biofeedback in form of an audio-signal will warn the patient if treatment recommendations like resting times are not followed. The control intervention will be pure instruction followed by measurements of load and quantity of steps. Control patients will not receive biofeedback upon transgression of recommendations.

    3. Consumption of analgesic medication after surgery [12 months]

      Consumption of analgesic medication following WHO grading. Data will be collected at any scheduled (2 and 6 weeks, 3 and 12 months) or unscheduled follow-up visits.

    4. Patient's quality of life after surgery [12 months]

      Quality of life will be analysed by using EuroQuality of Life Five Dimensions (EQ5D-5L) questionnaire at baseline and after 3 months and 12 months. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.

    5. Patient's satisfaction [12 months]

      Patient satisfaction will be documented after 2 weeks, 6 weeks, 3 months and 12 months by using net promotor score (NPS). NPS is the percentage of customers rating their likelihood to recommend the "service" to a friend or colleague as 9 or 10 ("promoters") minus the percentage rating this at 6 or below ("detractors") on a scale from 0 to 10.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Indication for hind- or midfoot arthrodesis

    • Informed Consent

    • Body weight < 90kg (according to Sens2Go manufacturers recommendations)

    Exclusion Criteria:
    • Physical or mental inability to follow weight-bearing recommendations (e.g. dementia, neurologic disease, upper extremity pathology)

    • Participation in a potentially interfering interventional trial during the last 30 day or before wash-out of any trial medication (e.g. steroids, medications affecting bone metabolism etc.)

    • Previous infection at the intended surgical site

    • Body weight > 90kg

    • Pregnancy

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Prof. Dr. med. Arno Frigg

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Prof. Dr. med. Arno Frigg, Prof. Dr. med., Klinik Hirslanden, Zurich
    ClinicalTrials.gov Identifier:
    NCT04732884
    Other Study ID Numbers:
    • BioPed
    First Posted:
    Feb 1, 2021
    Last Update Posted:
    Aug 23, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Prof. Dr. med. Arno Frigg, Prof. Dr. med., Klinik Hirslanden, Zurich

    Study Results

    No Results Posted as of Aug 23, 2022